Over 80% of Americans are exhibiting symptoms of depression related to the COVID-19 pandemic. Nearly 1 in 4 Americans have experienced suicidal or self-destructive thoughts.
Articles
Canadians Are Not OK, 83% of Canadians Report One Or More Symptoms of Depression With Many Turning To Substances To Cope With Negative Emotions During COVID-19 Pandemic, According to Field Trip Health's First Annual "State of Mind" Survey
Over 80% of Canadians are showing symptoms of depression related to the COVID-19 pandemic, with over half of Canadians feeling "down, depressed or hopeless".
Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update Strategic Partnerships Expand Drug Development Capabilities to More Efficiently and Rapidly Lead the Next Generation of Psychedelic-Assisted Therapeutics
Mydecine reports a net loss of CAD$5.2 million for Q1 2021, with cash and cash equivalents of CAD$11.3 million at the end of the quarter.
Politicians And Regulators Require Re-Education On Drugs
The Psychedelic Drug Revolution has begun. Standing in the way are politicians and regulators, saddled with archaic anti-drug phobias. They need to be educated.
A single dose of psilocybin has a lasting therapeutic effect on migraine headache, according to a new placebo-controlled study
Scientists have started to investigate whether psilocybin, the primary substance responsible for the psychedelic effects of “magic” mushrooms, could be helpful to those who suffer from migraine headache.
FDA Endorses Psychedelics 'Guided Experience' Model
The FDA has approved the use of MDMA by therapists -- to better prepare them to administer MDMA-assisted psychotherapy.
Alabama Governor Signs Medical Marijuana Legalization Bill
The governor of Alabama on Monday signed a bill to legalize medical marijuana in the state that was sent to her desk earlier this month.
Decriminalizing Psychedelic Drugs in California: As State Senate Considers Bill, Debate Continues
A bill to decriminalize psychedelic drugs is currently being considered by the California Legislature.
Psychedelic Drugs To The Rescue: Professional Sports Turn To Psychedelics
Traumatic Brain Injury is another major treatment market targeted by psychedelics R&D. TBIs are now a health crisis in many professional sports. Opportunity knocks.
MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline
MindMed reports a net loss of CAD$14 million for Q1, with US$160 million in cash and a total cash burn for the quarter of CAD$10 million.
Turn On, Tune In, Feel Better: The Rise of Psychedelic Therapy in Texas
On the day it opened in early May, Field Trip Health’s therapeutic facility in Houston’s uptown neighborhood looked a little like a high-end strip-mall spa. Dressed in a floral shirt, Matt Emmer, the company’s director of operations and business development, showed me the clinic’s amenities.
Media Coverage Of Psychedelic Drugs Soars
For a solid month, there has been an explosion in coverage of the psychedelic drug industry by the mainstream media.
World Boxing Council, Wesana Health Partnering To Examine Psychedelics As Potential Treatment For Traumatic Brain Injury
Since retiring from the National Hockey League in 2015 at age 30, Daniel Carcillo has dedicated his life to helping athletes and other people like himself who have suffered from traumatic brain injury.
The World Boxing Council and Wesana Health Announce Multi-Year Joint Efforts to Research the Impact of Psychedelics on Traumatic Brain Injury
Wesana inks a multi-year research agreement with the World Boxing Council on psychedelics therapy for Traumatic Brain Injury (TBI).
Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation
Numinus fills several key roles including a new Director of Mergers and Acquisitions and a new Chief Communications Officer.